文献速递中毒与环境急症重症综合管理与镇静镇痛

静脉脂肪乳解毒的体外研究:作用机制与临床前评估工具

In vitro studies of detoxification by intravenous fat emulsions: mechanism of action and preclinical assessment tools.
PubMed 文献 · Clin Toxicol (Phila) · 2026-08-10
一句话结论药物在模型血浆与静脉脂肪乳之间的分配系数≥10,可区分静脉脂肪乳可能有效的药物,为无特异性解毒剂的中毒提供体外筛选依据。

该体外研究用7种药物(溴西泮、布比卡因、苯海拉明、甲哌卡因、喹硫平、对乙酰氨基酚、维拉帕米)在模型血浆中评估静脉脂肪乳的萃取机制,其中5种有临床解毒成功报告为「应答者」,2种无应答为「非应答者」。结果显示所有应答者的药物萃取随乳剂浓度增加而显著增加,分配系数维持在10左右或以上;非应答者未显示该特征。药物从模型血浆分配至乳剂油滴主体是主要清除机制,油水界面吸附不影响该过程。分配系数阈值10可用于区分静脉脂肪乳是否能通过分配作用产生潜在临床解毒效果。

要点

  • 对5种临床报告解毒成功的药物(溴西泮、布比卡因、苯海拉明、甲哌卡因、喹硫平),药物萃取随静脉脂肪乳浓度增加而显著增加。
  • 分配系数(模型血浆与Intralipid®之间)≥10可区分静脉脂肪乳可能通过分配机制有效的药物,非应答者未达此阈值。
  • 药物分配至乳剂油滴主体是主要清除机制,油水界面吸附不影响该过程。
  • 该体外方法可用于无特异性解毒剂的中毒病例,辅助判断静脉脂肪乳是否可能有效。

适用人群与场景

  • 原文未提及具体适用人群的纳入/排除标准;研究为体外模型血浆实验,涉及药物中毒场景,结论外推至临床需谨慎。

诊断标准与关键阈值

  • 药物在模型血浆与静脉脂肪乳(Intralipid®)之间的分配系数阈值≥10,可用于区分静脉脂肪乳可能通过分配机制产生潜在解毒效果的药物。

处置流程与药物剂量

  • 原文未提及具体的静脉脂肪乳给药剂量、途径、频次或疗程。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 体外研究,7种药物(溴西泮、布比卡因、苯海拉明、甲哌卡因、喹硫平、对乙酰氨基酚、维拉帕米),其中5种为临床应答者,2种为非应答者。
  • 所有应答者药物萃取随乳剂浓度增加而显著增加,分配系数维持在10左右或以上。
  • 非应答者未显示分配系数≥10的特征,静脉脂肪乳不能通过分配机制有效清除。
  • 药物分配至乳剂油滴主体为主要清除机制,油水界面吸附不影响该过程。

证据类型、等级与局限

  • 体外研究,非临床研究,非RCT;原文未给出证据等级或推荐强度。
  • 局限:体外模型血浆实验,不能完全代表体内复杂环境;样本为7种药物;需临床验证。

对床旁实践的改变

  • 对于无特异性解毒剂的中毒病例,可参考药物分配系数≥10的体外阈值,辅助判断静脉脂肪乳是否可能通过分配机制有效,但不改变现有临床决策需结合患者具体情况。
  • 不适用于分配系数<10的药物(如对乙酰氨基酚、维拉帕米),静脉脂肪乳可能无效。
  • 常见陷阱:体外结果不能直接等同于临床疗效,需前瞻性验证。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

INTRODUCTION: The use of intravenous fat emulsions for treatment of drug intoxication still follows a trial-and-error approach, due to insufficient understanding of the mechanisms of the process and lack of predictive in vitro tools.

METHODS: We studied the physicochemical mechanisms of drug extraction from model plasma for seven drugs (bromazepam, bupivacaine, diphenhydramine, mepivacaine, quetiapine, paracetamol and verapamil) with clinical data for the detoxification efficiency of intravenous fat emulsions. Five of the studied drugs were labeled as "responders," due to clinical reports of successful patient detoxification, whereas the other two drugs were "non-responders," as they did not respond to intravenous fat emulsion treatment.

RESULTS: For all responders, drug extraction increased significantly with the increase of emulsion concentration, while the drug partition coefficient between model plasma and intravenous fat emulsion (Intralipid®) remained around or above 10: viz. the concentration of drug in the lipid phase was ten‑fold higher than in its concentration in the model plasma.

DISCUSSION: Drug partitioning from the model plasma to the bulk of the emulsion oil droplets was identified as the primary scavenging mechanism, whereas adsorption on the oil-water interface did not influence the process. For the studied seven drugs, it was established that a threshold value of 10 of the drug partition coefficient between model plasma and intravenous lipid emulsion can be successfully used to discriminate between drugs for which intravenous fat emulsions can lead to partitioning, indicating potential clinical efficiency in detoxification.

CONCLUSION: The approach described can be used to guide clinical practice in drug intoxication cases where a specific antidote is not available, expanding the treatment options of patients in intensive care conditions.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Krastev D, Atanasov V, Vinarov Z, et al. In vitro studies of detoxification by intravenous fat emulsions: mechanism of action and preclinical assessment tools. Clin Toxicol (Phila). 2026. PMID: 42572993. doi:10.1080/15563650.2026.2708998

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。